Long term virological, immunological and mortality outcomes in a cohort of HIV-infected female sex workers treated with highly active antiretroviral therapy in Africa

BMC Public Health

Volumn 11, Issue , 2011, Pages

  Huet, Charlotte ^a   Ouedraogo, Abdoulaye ^a   Konaté, Issouf ^a   Traore, Isidore ^a   Rouet, François ^a   Kaboré, Antoinette ^a   Sanon, Anselme ^a   Mayaud, Philippe ^b   Van De Perre, Philippe ^c   Nagot, Nicolas ^c  

^a CENTRE MURAZ   (Burkina Faso)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UMR 1058 University of Montpellier   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BURKINA FASO; CD4 LYMPHOCYTE COUNT; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INTERVIEW; MORTALITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PROSPECTIVE STUDY; PROSTITUTION; VIROLOGY; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BURKINA FASO; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; INTERVIEWS AS TOPIC; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; PROSPECTIVE STUDIES; SEX WORKERS; VIRAL LOAD;

EID: 80052835835     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-11-700     Document Type: Article

References (42)

1. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d'Ivoire. Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, Monga B, Maurice C, Nkengasong J, Konan-Koko R, Kadio A, Wiktor S, Lackritz E, Saba J, Chorba T, AIDS 2003 17 Suppl 3 5 15 14565604
2. Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Cote d'Ivoire. Seyler C, Anglaret X, Dakoury-Dogbo N, Messou E, Toure S, Danel C, Diakite N, Daudie A, Inwoley A, Maurice C, Tonwe-Gold B, Rouet F, N'Dri-Yoman T, Salamon R, Antivir Ther 2003 8 385 393 14640385 (Pubitemid 37351556)
3. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. Laurent C, Ngom Gueye NF, Ndour CT, Gueye PM, Diouf M, Diakhate N, Toure Kane NC, Laniece I, Ndir A, Vergne L, Ndoye I, Mboup S, Sow PS, Delaporte E, J Acquir Immune Defic Syndr 2005 38 14 17 10.1097/00126334- 200501010-00003 15608518 (Pubitemid 40094112)
4. Low prevalence of detectable HIV plasma viremia in patients treated with antiretroviral therapy in Burkina Faso and Mali. Boileau C, Nguyen VK, Sylla M, Machouf N, Chamberland A, Traore HA, Niamba PA, Diallo I, Maiga M, Cisse M, Rashed S, Tremblay C, J Acquir Immune Defic Syndr 2008 48 4 476 484 10.1097/QAI.0b013e31817dc416 18614917
5. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG, Lancet 2009 373 9657 48 57 10.1016/S0140-6736(08)61697-9 19038438
6. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. Ouedraogo A, Nagot N, Vergne L, Konate I, Weiss HA, Defer MC, Foulongne V, Sanon A, Andonaba JB, Segondy M, Mayaud P, Van de Perre P, AIDS 2006 20 2305 2313 10.1097/QAD. 0b013e328010238d 17117016 (Pubitemid 44789532)
7. Relation between HIV viral load and infectiousness: a model-based analysis. Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM, Lancet 2008 372 314 320 10.1016/S0140-6736(08)61115-0 18657710 (Pubitemid 352020440)
8. Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. Modjarrad K, Chamot E, Vermund SH, AIDS 2008 22 2179 2185 10.1097/QAD.0b013e328312c756 18832881
9. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. Fideli US, Allen SA, Musonda R, Trask S, Hahn BH, Weiss H, Mulenga J, Kasolo F, Vermund SH, Aldrovandi GM, AIDS Res Hum Retroviruses 2001 17 901 910 10.1089/088922201750290023 11461676 (Pubitemid 32881333)
10. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, Meehan MO, Lutalo T, Gray RH, N Engl J Med 2000 342 921 929 10.1056/NEJM200003303421303 10738050 (Pubitemid 30177052)
11. Can antiretroviral therapy eliminate HIV transmission? De Cock KM, Gilks CF, Lo YR, Guerma T, Lancet 2009 373 9657 7 9 10.1016/S0140-6736(08)61732-8 19038440
12. Spectrum of commercial sex activity in Burkina Faso: classification model and risk of exposure to HIV. Nagot N, Ouangre A, Ouedraogo A, Cartoux M, Huygens P, Defer MC, Zekiba T, Meda N, Van de Perre P, J Acquir Immune Defic Syndr 2002 29 517 521 11981369 (Pubitemid 34456344)
13. The central role of clients of female sex workers in the dynamics of heterosexual HIV transmisson in sub-Saharan Africa. Alary M, Lowndes CM, AIDS 2004 18 945 947 10.1097/00002030-200404090-00013 15060443 (Pubitemid 38553716)
14. Commercial sex and the spread of HIV in four cities in sub-Saharan Africa. Morison L, Weiss HA, Buve A, Carael M, Abega SC, Kaona F, Kanhonou L, Chege J, Hayes RJ, Aids 2001 15 Suppl 4 61 69 11686467
15. Transactional sex is the driving force in the dynamics of HIV in Accra, Ghana. Cote AM, Sobela F, Dzokoto A, Nzambi K, Asamoah-Adu C, Labbe AC, Masse B, Mensah J, Frost E, Pepin J, AIDS 2004 18 917 925 10.1097/00002030-200404090- 00009 15060439 (Pubitemid 38553712)
16. Decline in the prevalence of HIV and sexually transmitted diseases among female sex workers in Cotonou, Benin, 1993-1999. Alary M, Mukenge-Tshibaka L, Bernier F, Geraldo N, Lowndes CM, Meda H, Gnintoungbe CA, Anagonou S, Joly JR, AIDS 2002 16 463 470 10.1097/00002030-200202150-00019 11834959 (Pubitemid 34165379)
17. Increase in condom use and decline in HIV and sexually transmitted diseases among female sex workers in Abidjan, Cote d'Ivoire, 1991-1998. Ghys PD, Diallo MO, Ettiegne-Traore V, Kale K, Tawil O, Carael M, Traore M, Mah-Bi G, De Cock KM, Wiktor SZ, Laga M, Greenberg AE, AIDS 2002 16 251 258 10.1097/00002030-200201250-00015 11807310 (Pubitemid 34118573)
18. Is sexually transmitted infection management among sex workers still able to mitigate the spread of HIV infection in West Africa? Nagot N, Ouedraogo A, Ouangre A, Cartoux M, Defer MC, Meda N, Van de Perre P, J Acquir Immune Defic Syndr 2005 39 454 458 10.1097/01.qai.0000152399.54648.b9 16010169 (Pubitemid 41003792)
19. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. Nagot N, Ouedraogo A, Foulongne V, Konate I, Weiss HA, Vergne L, Defer MC, Djagbare D, Sanon A, Andonaba JB, Becquart P, Segondy M, Vallo R, Sawadogo A, Van de Perre P, Mayaud P, N Engl J Med 2007 356 790 799 10.1056/NEJMoa062607 17314338 (Pubitemid 46294611)
20. Safe and effective use of antiretroviral treatments in adults with particular reference to resource limited settings. World Health Organization, Geneva: WHO/UNAIDS 2000
21. WHO technical report series. WHO expert consultation on cotrimoxazole prophylaxis in HIV infection, Geneva: WHO 2006 http://www.who.int/hiv/pub/ meetingreports/ctx/en accessed on 27 July 2010
22. Serological diagnosis of human immuno-deficiency virus in Burkina Faso: reliable, practical strategies using less expensive commercial test kits. Meda N, Gautier-Charpentier L, Soudre RB, Dahourou H, Ouedraogo-Traore R, Ouangre A, Bambara A, Kpozehouen A, Sanou H, Valea D, Ky F, Cartoux M, Barin F, Van de Perre P, Bull World Health Organ 1999 77 731 739 10534896 (Pubitemid 29477023)
23. Joint United Nations Programme on HIV/AIDS (UNAIDS)-WHO. Revised recommendations for the selection and use of HIV antibody tests. Wkly Epidemiol Rec 1997 72 81 87 9238418
24. Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. Rouet F, Chaix ML, Nerrienet E, Ngo-Giang-Huong N, Plantier JC, Burgard M, Peeters M, Damond F, Ekouevi DK, Msellati P, Ferradini L, Rukobo S, Marechal V, Schvachsa N, Wakrim L, Rafalimanana C, Rakotoambinina B, Viard JP, Seigneurin JM, Rouzioux C, J Acquir Immune Defic Syndr 2007 45 380 388 10.1097/QAI.0b013e3180640cf5 17468666 (Pubitemid 47057665)
25. Performance of commercially available enzyme immunoassays for detection of antibodies against herpes simplex virus type 2 in African populations. van Dyck E, Buve A, Weiss HA, Glynn JR, Brown DW, De Deken B, Parry J, Hayes RJ, J Clin Microbiol 2004 42 7 2961 2965 10.1128/JCM.42.7.2961-2965.2004 15243045 (Pubitemid 38938043)
26. Echelle ANRS de Cotation de la Gravité des Evénements Indésirables chez l'adulte. Agence Nationale de Recherche sur le Sida et les hépatites virales, Version no. 6 du 9 septembre 2003
27. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Brinkhof MW, Dabis F, Myer L, Bangsberg DR, Boulle A, Nash D, et al. Bull World Health Organ 2008 86 559 567 10.2471/BLT.07.044248 18670668 (Pubitemid 351931216)
28. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, Laniece I, Dieng AB, Diouf A, Laurent C, Mboup S, Sow PS, Delaporte E, AIDS 2006 20 1181 1189 10.1097/01.aids.0000226959. 87471.01 16691070 (Pubitemid 43786107)
29. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote d'Ivoire: 2-year outcomes and determinants. Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, Duvignac J, Diakite N, Karcher S, Grundmann C, Marlink R, Dabis F, Anglaret X, AIDS 2008 22 873 882 10.1097/QAD.0b013e3282f768f8 18427206 (Pubitemid 351563837)
30. Antiretroviral therapy and early mortality in South Africa. Boulle A, Bock P, Osler M, Cohen K, Channing L, Hilderbrand K, Mothibi E, Zweigenthal V, Slingers N, Cloete K, Abdullah F, Bull World Health Organ 2008 86 678 687 10.2471/BLT.07.045294 18797643
31. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg DR, Balestre E, Sterne JA, May M, Egger M, Lancet 2006 367 9513 817 824 16530575 (Pubitemid 43363368)
32. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R, AIDS 2008 22 1897 1908 10.1097/QAD.0b013e32830007cd 18784453
33. Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings. Marazzi MC, Liotta G, Germano P, Guidotti G, Altan AD, Ceffa S, Lio MM, Nielsen-Saines K, Palombi L, AIDS Res Hum Retroviruses 2008 24 555 560 10.1089/aid.2007.0217 18366314 (Pubitemid 351571039)
34. Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. Keiser O, Orrell C, Egger M, Wood R, Brinkhof MW, Furrer H, van Cutsem G, Ledergerber B, Boulle A, PLoS Med 2008 5 7 148 10.1371/journal.pmed.0050148 18613745
35. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA, Lancet 2002 360 119 129 10.1016/S0140-6736(02)09411-4 12126821 (Pubitemid 34786200)
36. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, Reuter H, Ntwana N, Goemaere E, AIDS 2004 18 887 895 10.1097/00002030-200404090-00006 15060436 (Pubitemid 38553709)
37. Genital herpes and human immunodeficiency virus: double trouble. Celum C, Levine R, Weaver M, Wald A, Bull World Health Organ 2004 82 447 453 15356938 (Pubitemid 38828431)
38. HIV-1 superinfections in a cohort of commercial sex workers in Burkina Faso as assessed by an autologous heteroduplex mobility procedure. Manigart O, Courgnaud V, Sanou O, Valea D, Nagot N, Meda N, Delaporte E, Peeters M, Van de Perre P, AIDS 2004 18 1645 1651 10.1097/01.aids.0000131333.30548.db 15280775 (Pubitemid 39095781)
39. Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events. Hoffmann CJ, Fielding KL, Charalambous S, Sulkowski MS, Innes C, Thio CL, Chaisson RE, Churchyard GJ, Grant AD, AIDS 2008 22 67 74 10.1097/QAD.0b013e3282f2306e 18090393 (Pubitemid 350294879)
40. The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. Hamers RL, Derdelinckx I, van Vugt M, Stevens W, Rinke de Wit TF, Schuurman R, Antivir Ther 2008 13 625 639 18771046
41. HIV drug resistance pattern among HAART-exposed patients with suboptimal virological response in Ouagadougou, Burkina Faso. Tebit DM, Sangare L, Makamtse A, Yameogo S, Somlare H, Bado G, Kouldiaty BG, Sathiandee K, Tiba F, Sanou I, Ouedraogo-Traore R, Zoungrana L, Diallo I, Drabo JY, Krausslich HG, J Acquir Immune Defic Syndr 2008 49 17 25 10.1097/QAI.0b013e318182d2bc 18667925
42. Cost-effectiveness of HIV treatment in resource-poor settings - the case of Cote d'Ivoire. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, Hsu HE, Kimmel A, Holmes C, Kaplan JE, Freedberg KA, N Engl J Med 2006 355 11 1141 1153 10.1056/NEJMsa060247 16971720 (Pubitemid 44394920)